Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Hanmi Pharmaceutical will get US$10 million from Merck Sharp & Dohme (MSD) as initial contract payment in an $860 million exclusive licensing deal for the development, manufacture, and commercialization of its liver treatment candidate material efinopegdutide.
Under the deal, Hamni will be getting royalty payments from MSD with the development of the efinopegdutide.
However, the overall payment MSD will give Hanmi is contingent on regulatory permission and the drug's success in the market.
Efinopegdutide is for treating nonalcoholic steatohepatitis (NASH), a condition where the liver suffers inflammation and damage due to excess fat in the organ.
The South Korean pharmaceutical firm claimed findings from the latest phase 2 studies have provided compelling clinical evidence that the material can be used on people with NASH.
Efinopegdutide was originally developed for insulin secretion and obesity control, in cooperation with Janssen Pharmaceutica.
A 2015 deal to develop and market the drug through due to shortfalls related to blood sugar level control.
